We write in response to several assertions stated in this letter.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Baloxavir for influenza: enrichment obscured lack of effect in North-American adults.Eur J Intern Med. 2019; 62 (Epub 2019 Mar 8): e8-e9https://doi.org/10.1016/j.ejim.2018.12.002
- Baloxavir marboxil for uncomplicated influenza in adults and adolescents.N Engl J Med. 2018 Sep 6; 379: 913-923https://doi.org/10.1056/NEJMoa1716197
- Exploring clinical and antiviral efficacy of baloxavir marboxil in a phase 3, randomized, double-blind, placebo- and active-controlled study of otherwise healthy adults/adolescents in seasonal influenza: impact on regional participants, treatment time and influenza type B virus infection (CAPSTONE-1 study); IDWeek.2018 (Abstract 1645)
- LB16. phase 3 trial of baloxavir marboxil in high-risk influenza patients (CAPSTONE-2 Study).Open Forum Infect Dis. 2018; 5 (Published 2018 Nov 26): S764-S765https://doi.org/10.1093/ofid/ofy229.2190
- Adjusted Kaplan–Meier estimator and log-rank test with inverse probability of treatment weighting for survival data.Stat Med. 2005; 24: 3089-3110https://doi.org/10.1002/sim.2174
- Clinical signs and symptoms predicting influenza infection.Arch Intern Med. 2000; 160: 3243-3247
Article info
Publication history
Published online: January 15, 2020
Accepted:
November 7,
2019
Received:
October 24,
2019
Identification
Copyright
© 2019 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Baloxavir for influenza: Enrichment obscured lack of effect in North-American adultsEuropean Journal of Internal MedicineVol. 62
- PreviewThe FDA recently approved the use of baloxavir marboxil (baloxavir) in patients aged 12–64 years with uncomplicated influenza [1]. The effectiveness of baloxavir had been tested in one phase III trial named CAPSTONE-1 [2]. It consisted of two subtrials: one subtrial compared baloxavir (40 mg once) with placebo and oseltamivir in adult patients, and the other baloxavir with placebo in adolescent patients (total n = 1436). The trial was performed in Japan, the United States, and Canada. In the reported primary efficacy analysis, baloxavir reduced the time to alleviation of flu symptoms with 26.5 hours compared to placebo.
- Full-Text
- Preview
